

Ref no: 072040820
From: Commercial
Date: 04/08/20
Subject: Atopic dermatitis

REQUEST & RESPONSE

1. How many patients were treated within your Trust with the following drugs within the specified time periods?

St Helens and Knowsley Teaching Hospitals NHS Trust does not hold the information in the requested format. National coding does not distinguish between the following drugs Apremilast, Adalimumab, Etanercept, Infliximab and Secukinumab and have been counted as a group.

The Trust cannot determine if a patient has been treated with the above drugs only if they have been coded with the drug during their inpatient spell.

Drug	Number of patients treated between 01 February 2017 and 31 July 2018	Number of patients treated between 01 August 2018 and 31 January 2020
Apremilast, Adalimumab, Etanercept, Infliximab, Secukinumab	11	652
Dupilumab	<*	<*
Ustekinumab	<*	141

2. How many patients were treated within your Trust for atopic dermatitis within the specified time periods?

The Trust cannot determine if a patient has been treated for atopic dermatitis. Submitted information is for patients who have had a coded diagnosis of atopic dermatitis within their inpatient stay.

Number of patients treated for atopic dermatitis between 01 February 2017 and 31 July 2018	Number of patients treated for atopic dermatitis between 01 August 2018 and 31 January 2020
23	29

3. How many patients were treated within your Trust with the following drugs for atopic dermatitis within the specified time periods?

The Trust cannot determine if a patient has been treated with the following drugs for atopic dermatitis.

The information we have provided in questions 1 and 2 relates to patients who have had a coded diagnosis of atopic dermatitis and also have been coded with one of the below drugs within their inpatient stay.

These coded diagnoses may not necessarily be their primary diagnosis.

Of the patients recorded in question 2, no patients have one of the drugs coded against their stay.

Drug	Number of patients treated for atopic dermatitis between 01 February 2017 and 31 July 2018	Number of patients treated for atopic dermatitis between 01 August 2018 and 31 January 2020
Apremilast		
Adalimumab		
Dupilumab		
Etanercept		
Infliximab		
Secukinumab		
Ustekinumab		

4. Please specify how patients treated with the following drugs are coded (OPCS code) within your trust:

Drug	OPCS code (e.g. X385 subcutaneous immunotherapy)
Apremilast	X921
Adalimumab	X921
Dupilumab	X386 given as a subcutaneous injection
Etanercept	X921
Infliximab	X921
Secukinumab	X921
Ustekinumab	X891

5. Please provide the number of patients treated in the homecare setting for atopic dermatitis within the specified time periods:

The Trust cannot distinguish if patients are treated in a homecare setting, as such this information is not held.

Number of patients treated in the homecare setting for atopic dermatitis between 01 February 2017 and 31 July 2018	Number of patients treated in the homecare setting for atopic dermatitis between 01 August 2018 and 31 January 2020

6. How many of your Trust's homecare patients were treated with the following drugs for atopic dermatitis within the specified time periods?

The Trust cannot distinguish if patients are treated in a homecare setting, as such this information is not held.

Drug	Number of patients treated for atopic dermatitis between 01 February 2017 and 31 July 2018	Number of patients treated for atopic dermatitis between 01 August 2018 and 31 January 2020
Apremilast		
Adalimumab		
Dupilumab		
Etanercept		
Infliximab		
Secukinumab		
Ustekinumab		

* **Please note:** We are unable to provide precise figures when those figures refer to individuals in volumes of 5 or less due to the risk that individuals will be re-identified, as we are required to protect their identity under the General Data Protection Regulations & Data Protection Act 2018. In such circumstances sections 40(2) and (3) of the Freedom of Information Act apply. In this case, our view is that disclosure would breach the first data protection principle. This states that personal data should be processed "lawfully, fairly and in a transparent manner". It is the lawful aspect of this principle which, in our view, would be breached by disclosure. In such circumstances section 40 confers an absolute exemption on disclosure.